ASCO 2024 Highlights: Long-Term Data and the Future of Combination Therapies in Melanoma

EP: 1.ASCO 2024: Addressing Unmet Needs in Melanoma Treatment and Management

EP: 2.Key Findings from the NADINA Trial at ASCO 2024

EP: 3.ASCO 2024: Impact of RELATIVITY-047 on Metastatic Melanoma Management

Now Viewing

EP: 4.ASCO 2024 Highlights: Long-Term Data and the Future of Combination Therapies in Melanoma

EP: 5.Highlights from ASCO 2024: Individualized Neoantigen Therapy in Melanoma

EP: 6.ASCO 2024: Emerging Data on Brenetafusp (IMC-F106C) ImmTAC Bispecific in Melanoma

EP: 7.Melanoma Research Beyond ASCO 2024: Upcoming Advances and Insights

Video content above is prompted by the following:

• What is the value of long-term follow-up data in melanoma? How does this impact use of treatment regimens?
• How do you foresee the role of combination therapies evolving in the treatment of melanoma over the next few years?